Market Overview:
The global CRISPR & Cas genes market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for CRISPR technology from biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations (CROs). Additionally, the increasing focus on precision medicine is also contributing to the growth of this market. The vector-based Cas segment is expected to account for the largest share of the global CRISPR & Cas genes market in 2018. This segment is expected to grow at a CAGR of XX% during the forecast period. The DNA-free Cas segment is projected to grow at a higher rate than other segments during the forecast period. This segment is projected to grow at a CAGR of XX%.
Product Definition:
CRISPR (clustered regularly interspaced short palindromic repeats) are DNA sequences that occur in the genomes of bacteria and archaea. They are found adjacent to cas genes, which encode proteins involved in CRISPR immunity. The function of CRISPR arrays is not fully understood, but they may play a role in protecting cells from invading viruses or plasmids. Cas proteins are also involved in CRISPR immunity and may help destroy foreign genetic material.
The use of CRISPR-Cas9 technology has revolutionized gene editing and holds great potential for treating diseases caused by mutations in human genes. The Cas9 protein can be directed to specific locations on the genome where it can cut the DNA strands, allowing new genes to be inserted or deleted.
Vector-based Cas:
The global CRISPR & Cas9 gene-editing market size was valued at USD 2.89 billion in 2016 and is expected to grow at a CAGR of XX% during the forecast period.
DNA-free Cas:
DNA-free Cas is a protein that has no nucleic acid content in it. It is produced by the body to kill viruses and bacteria. DNA-free Cas can also be used as an immunosuppressive drug to prevent rejection of a transplanted organ, which makes it very popular among surgeons performing transplantation procedures.
The global CRISPR &Cas genes market size was valued at USD 2 billion in 2018.
Application Insights:
The biotechnology and pharmaceutical companies segment dominated the global market in 2017. This can be attributed to the rising usage of CRISPR-Cas systems for editing genomes of human somatic cells, stem cells, and induced pluripotent stem cells (iPSCs). Furthermore, this technique is being widely used for research purposes across various other applications such as plant genome engineering.
CRISPR has revolutionized genetic engineering by providing a high efficiency method that allows scientists to precisely edit genomes at fast pace. It has been widely applied in plant genome engineering due to its ability to introduce mutations with high specificity and ease. In addition, it also helps improve gene targeting efficacy by enhancing Cas9 nuclease activity through dual-RNA guided DNA end-joining process during target engagement.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2016. The growth can be attributed to the presence of a large number of CROs that are involved with genome editing research and development activities. Moreover, government funding for genome editing research is also one factor responsible for this dominance. For instance, as per a recent study published by National Institutes of Health (U.S.), researchers from U.S.-based institutions received approximately USD X million between 2009 and 2014 for their work related to using Crispr-Cas systems in human diseases treatment or diagnosis [1].
Asia Pacific is expected to grow at an exponential rate during the forecast period owing to increasing investments from private companies as well as public entities towards R&D activities pertaining gene editing technology applications in agriculture and other industries [2].
Growth Factors:
- Increasing demand for genetically modified crops
- Rising prevalence of genetic disorders and chronic diseases
- Growing investments in CRISPR & Cas Genes research and development
- Proliferation of precision medicine therapies
- Technological advancements in CRISPR & Cas Genes editing
Scope Of The Report
Report Attributes
Report Details
Report Title
CRISPR & Cas Genes Market Research Report
By Type
Vector-based Cas, DNA-free Cas, Cell Line Engineering
By Application
Biotechnology and Pharmaceutical Companies, Academics and Government Research Institutes, Contract Research Organizations (CROs)
By Companies
CRISPR Therapeutics, AstraZeneca, Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd., Horizon Discovery Group Plc, Genscrip, Danaher Corporation, Intellia Therapeutics, Inc., Lonza, Merck KGaA, New England BioLabs, Takara Bio, Inc., Synthego, Mammoth Biosciences, Inscripta, Inc., Cibus
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
212
Number of Tables & Figures
149
Customization Available
Yes, the report can be customized as per your need.
Global CRISPR & Cas Genes Market Report Segments:
The global CRISPR & Cas Genes market is segmented on the basis of:
Types
Vector-based Cas, DNA-free Cas, Cell Line Engineering
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biotechnology and Pharmaceutical Companies, Academics and Government Research Institutes, Contract Research Organizations (CROs)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CRISPR Therapeutics
- AstraZeneca
- Addgene
- Caribou Biosciences, Inc.
- Cellectis
- Editas Medicine, Inc.
- Egenesis
- F. Hoffmann-La Roche Ltd.
- Horizon Discovery Group Plc
- Genscrip
- Danaher Corporation
- Intellia Therapeutics, Inc.
- Lonza
- Merck KGaA
- New England BioLabs
- Takara Bio, Inc.
- Synthego
- Mammoth Biosciences
- Inscripta, Inc.
- Cibus
Highlights of The CRISPR & Cas Genes Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Vector-based Cas
- DNA-free Cas
- Cell Line Engineering
- By Application:
- Biotechnology and Pharmaceutical Companies
- Academics and Government Research Institutes
- Contract Research Organizations (CROs)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CRISPR & Cas Genes Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CRISPR is a gene editing tool that uses an RNA molecule to target and edit specific DNA sequences. Cas genes are responsible for the CRISPR-associated (Cas) defense system in bacteria. When invading viruses or other foreign DNA molecules try to enter the cell, Cas proteins recognize and destroy them.
Some of the major players in the crispr & cas genes market are CRISPR Therapeutics, AstraZeneca, Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd., Horizon Discovery Group Plc, Genscrip, Danaher Corporation, Intellia Therapeutics, Inc., Lonza, Merck KGaA, New England BioLabs, Takara Bio, Inc., Synthego, Mammoth Biosciences, Inscripta, Inc., Cibus.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CRISPR & Cas Genes Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CRISPR & Cas Genes Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CRISPR & Cas Genes Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CRISPR & Cas Genes Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CRISPR & Cas Genes Market Size & Forecast, 2018-2028
4.5.1 CRISPR & Cas Genes Market Size and Y-o-Y Growth
4.5.2 CRISPR & Cas Genes Market Absolute $ Opportunity
Chapter 5 Global CRISPR & Cas Genes Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 CRISPR & Cas Genes Market Size Forecast by Type
5.2.1 Vector-based Cas
5.2.2 DNA-free Cas
5.2.3 Cell Line Engineering
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global CRISPR & Cas Genes Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 CRISPR & Cas Genes Market Size Forecast by Applications
6.2.1 Biotechnology and Pharmaceutical Companies
6.2.2 Academics and Government Research Institutes
6.2.3 Contract Research Organizations (CROs)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CRISPR & Cas Genes Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CRISPR & Cas Genes Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America CRISPR & Cas Genes Analysis and Forecast
9.1 Introduction
9.2 North America CRISPR & Cas Genes Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America CRISPR & Cas Genes Market Size Forecast by Type
9.6.1 Vector-based Cas
9.6.2 DNA-free Cas
9.6.3 Cell Line Engineering
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America CRISPR & Cas Genes Market Size Forecast by Applications
9.10.1 Biotechnology and Pharmaceutical Companies
9.10.2 Academics and Government Research Institutes
9.10.3 Contract Research Organizations (CROs)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe CRISPR & Cas Genes Analysis and Forecast
10.1 Introduction
10.2 Europe CRISPR & Cas Genes Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe CRISPR & Cas Genes Market Size Forecast by Type
10.6.1 Vector-based Cas
10.6.2 DNA-free Cas
10.6.3 Cell Line Engineering
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe CRISPR & Cas Genes Market Size Forecast by Applications
10.10.1 Biotechnology and Pharmaceutical Companies
10.10.2 Academics and Government Research Institutes
10.10.3 Contract Research Organizations (CROs)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific CRISPR & Cas Genes Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific CRISPR & Cas Genes Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific CRISPR & Cas Genes Market Size Forecast by Type
11.6.1 Vector-based Cas
11.6.2 DNA-free Cas
11.6.3 Cell Line Engineering
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific CRISPR & Cas Genes Market Size Forecast by Applications
11.10.1 Biotechnology and Pharmaceutical Companies
11.10.2 Academics and Government Research Institutes
11.10.3 Contract Research Organizations (CROs)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America CRISPR & Cas Genes Analysis and Forecast
12.1 Introduction
12.2 Latin America CRISPR & Cas Genes Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America CRISPR & Cas Genes Market Size Forecast by Type
12.6.1 Vector-based Cas
12.6.2 DNA-free Cas
12.6.3 Cell Line Engineering
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America CRISPR & Cas Genes Market Size Forecast by Applications
12.10.1 Biotechnology and Pharmaceutical Companies
12.10.2 Academics and Government Research Institutes
12.10.3 Contract Research Organizations (CROs)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) CRISPR & Cas Genes Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) CRISPR & Cas Genes Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) CRISPR & Cas Genes Market Size Forecast by Type
13.6.1 Vector-based Cas
13.6.2 DNA-free Cas
13.6.3 Cell Line Engineering
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) CRISPR & Cas Genes Market Size Forecast by Applications
13.10.1 Biotechnology and Pharmaceutical Companies
13.10.2 Academics and Government Research Institutes
13.10.3 Contract Research Organizations (CROs)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CRISPR & Cas Genes Market: Competitive Dashboard
14.2 Global CRISPR & Cas Genes Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CRISPR Therapeutics
14.3.2 AstraZeneca
14.3.3 Addgene
14.3.4 Caribou Biosciences, Inc.
14.3.5 Cellectis
14.3.6 Editas Medicine, Inc.
14.3.7 Egenesis
14.3.8 F. Hoffmann-La Roche Ltd.
14.3.9 Horizon Discovery Group Plc
14.3.10 Genscrip
14.3.11 Danaher Corporation
14.3.12 Intellia Therapeutics, Inc.
14.3.13 Lonza
14.3.14 Merck KGaA
14.3.15 New England BioLabs
14.3.16 Takara Bio, Inc.
14.3.17 Synthego
14.3.18 Mammoth Biosciences
14.3.19 Inscripta, Inc.
14.3.20 Cibus
